Supplementary Online Content


**eMethods 1.** Definition of Adverse Events
**eMethods 2.** Predefined Secondary Outcomes

This supplementary material has been provided by the authors to give readers additional information about their work.
**eMethods 1. Definition of Adverse Events**

1) **Cardiac Arrhythmia**: Sustained abnormality in cardiac rhythm (bradycardia, tachycardia, or abnormal rhythm disturbance) requiring evaluation by EKG and therapy with antiarrhythmia medications.

2) **Persistent acidosis**: Developing after 3 hours of intervention and persisting > 3 hours. The pH was less than 2 SD or base deficit greater than 2 SD of the mean, in an algorithm based on the prior NICHD NRN hypothermia trial

3) **Thrombosis**: Diagnosis of major artery or venous system occlusion

4) **Major Bleeding**: Overt bleeding, platelet count <40,000/L with or without abnormal coagulation studies

5) **Alteration of skin integrity**: Presence of erythema, sclerema, cyanosis or subcutaneous fat necrosis

6) **Death**
eMethods 2. Predefined Secondary Outcomes:

1) Hypotension and use of inotropic agents
2) Blood or platelet transfusions
3) Persistent pulmonary hypertension, treatment with Inhaled Nitric Oxide and ECMO
4) Documented seizures
5) Oliguria or Anuria
6) Hepatic Dysfunction
7) Culture proven infection
8) Disseminated intravascular coagulopathy
9) Hypoglycemia, hypocalcemia,
10) Length of hospital stay, oxygen days and ventilation days
11) Gastric fundal plication, gastrostomy and tracheostomy
12) Home therapy with Ventilation, oxygen, gavage or gastrostomy tube and anticonvulsant medication